Pexion (imepitoin) - QN03AX90
Updated on site: 21-Sep-2017
|Manufacturer:||Boehringer Ingelheim Vetmedica GmbH|
This document is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This document cannot replace a
What is Pexion?
Pexion is a veterinary medicine that contains imepitoin. It is available as tablets (100 mg and 400 mg).
What is Pexion used for?
Pexion is used in dogs to reduce the frequency of generalised seizures (fits affecting most or all of the brain) due to epilepsy of unknown causes (idiopathic). It should be used after careful evaluation of alternative treatment options.
Treatment with Pexion should be started at a dose of 10 mg per kg bodyweight twice a day. If seizures are not adequately controlled after one week, the veterinary surgeon may increase the dose in weekly increments to a maximum of 30 mg per kg bodyweight twice a day.
How does Pexion work?
The active substance in Pexion, imepitoin, is an
effect on calcium channels. These are pores which let calcium move into the nerve cells allowing electrical impulses to be transmitted between nerve cells. This may also help in controlling seizures.
How has Pexion been studied?
Pexion has been compared to phenobarbital (another
- Novem - Boehringer Ingelheim Vetmedica GmbH
- Bovela - Boehringer Ingelheim Vetmedica GmbH
- Metacam - Boehringer Ingelheim Vetmedica GmbH
- Ingelvac circoflex - Boehringer Ingelheim Vetmedica GmbH
- Semintra - Boehringer Ingelheim Vetmedica GmbH
Prescription drugs listed. Manufacturer: "Boehringer Ingelheim Vetmedica GmbH"
What benefit has Pexion shown during the studies?
Pexion reduced the average number of generalised seizures from 2.3 to 1.1 per month after 20 weeks of treatment compared with a reduction of 2.4 seizures to 1.1 per month with phenobarbital. During the evaluation phase of 12 weeks, 47% (30 out of 64) of Pexion treated dogs were free from generalised seizures, whilst 58% (51 out of 88) of phenobarbital treated dogs had no seizures.
Even though the proportion of seizure free dogs was lower with Pexion than with phenobarbital, some dogs were well controlled with Pexion. As side effects were less frequent than with phenobarbital, Pexion is a suitable treatment option for some dogs, considering in particular its safety profile.
What is the risk associated with Pexion?
Mild and generally
Pexion must not be used in dogs that are hypersensitive (allergic) to the active ingredient or to any of the ingredients. It must also not be used in dogs with severely impaired liver, kidney or heart function.
The effectiveness of Pexion to treat dogs with status epilepticus and cluster seizures has not been studied. Therefore, Pexion should not be used as a primary treatment for dogs with cluster seizures (group of seizures occurring close together) and status epilepticus (continual seizures).
What are the precautions for the person who gives the medicine or comes into contact with the animal?
In case of accidental ingestion, especially by a child, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
To prevent accidental ingestion, the bottle cap should be replaced immediately after withdrawing the required number of tablets for one dose.
Why has Pexion been approved?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Pexion exceed the risks for the approved indications and recommended that Pexion be given a marketing authorisation. The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Other information about Pexion:
The European Commission granted a marketing authorisation valid throughout the European Union, for Pexion on 25 February 2013. Information on the prescription status of this product may be found on the label/outer package.
This summary was last updated on 25 February 2013.